News

# Novavax delays its COVID-19 vaccine timeline

Table of Contents

“#
Novavax delays its COVID-19 vaccine timeline
”

Shortages slowing production; biotech won’t request regulatory approvals until September

Novavax Inc. has delayed plans to seek regulatory clearances for its COVID-19 vaccine, while shortages in raw materials are slowing the ramp-up of production of doses, the company said.

The delays may set back efforts to increase vaccinations in developing countries, which have been dealing with limited doses of currently available shots and are looking forward to Novavax’s.

Previously, Novavax
NVAX,

-8.81%

said it expected to complete requests for regulatory authorizations of its COVID-19 vaccine in the U.S., the U.K. and other European countries by the end of June. Now, the company said Monday it expects to complete those filings by the end of September.

Novavax said it also pushed back the timetable for when it expects to reach full production output of about 150 million doses a month, to the fourth quarter this year from a prior target of the third quarter.

An expanded version of this report appears on WSJ.com.

Also popular on WSJ.com:

Catholic schools are losing students at record rates, and hundreds are closing.

The breakout cities on the forefront of America’s economic recovery.

Peter Loftus

If you liked the article, do not forget to share it with your friends. Follow us on Google News too, click on the star and choose us from your favorites.